GlassScriptPhysician profile
Brian W Beluch
NPI 1811142508
$25,448.48
in general payments reported to CMS, 2019-2025
20 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,326 · 2020: $2,897 · 2021: $994 · 2022: $3,849 · 2023: $4,174 · 2024: $9,520 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $1,649 · Travel and Lodging: $1,391 · Consulting Fee: $413 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,656.25 |
| Food and Beverage | $1,648.56 |
| Travel and Lodging | $1,390.67 |
| Consulting Fee | $412.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17,450.50 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Medtronic Minimed, INC. | $5,348.18 | 2019-2020 | |
| Medtronic, INC. | $1,570.66 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $330.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $161.10 | 2019 | |
| Insulet Corporation | $121.20 | 2025 | Omnipod |
| Lilly USA, LLC | $107.00 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $82.73 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $63.95 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $26.24 | 2019 | |
| Sequel Med Tech, LLC | $25.95 | 2025 | Twiist |
| Antares Pharma, INC. | $24.00 | 2019 | |
| Radius Health, INC. | $22.77 | 2019 | |
| Becton, Dickinson and Company | $21.55 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.08 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.49 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $15.36 | 2024 | |
| Xeris Pharmaceuticals, INC. | $15.28 | 2025 | Gvoke Hypopen |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Shire North American Group INC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Beluch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.